Brief: Zim Laboratories Gets Marketing Authorization For Dabigatran Etexilate Capsules In Italy, Europe
19/05/2026 14:28
May 19 (Reuters) - Zim Laboratories Ltd ZIML.NS: ZIM LABORATORIES - GETS MARKETING AUTHORIZATION FOR DABIGATRAN ETEXILATE CAPSULES IN ITALY, EUROPE Source text: [ID:] Further company coverage: ZIML.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Zim Laboratories
See all newsBrief: Zim Laboratories Gets Marketing Authorization For Dabigatran Etexilate Capsules In Italy, Europe
Brief: Zim Laboratories March-Quarter Consol Net Profit 37.4 Mln Rupees
Brief: Zim Laboratories To Consider Fund Raising Via Securities Issuance
Brief: Zim Laboratories Gets Marketing Authorization For Tamsulosin + Dutasteride Capsules In Australia
India's Zim Laboratories up after getting marketing authorization for migraine drug in Australia